Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making ...

The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

For patients with mild-to-moderate tricuspid regurgitation (TR) on top of degenerative mitral regurgitation (MR), tricuspid annuloplasty done at the time of mitral valve surgery can prevent disease ...

Edwards Lifesciences (EW) announced its SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal ...

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first ...

LONDON — Opinions about the relative value of interventions to control mitral regurgitation secondary to heart failure might be altered by two large randomized trials. The RESHAPE-HF2 trial showed ...

For high-risk surgical patients with severe symptomatic mitral regurgitation (MR), insertion of the Tendyne transcatheter mitral valve replacement (TMVR; Abbott) using a cardiac transapical approach ...

Mitral valve prolapse treatment aims to relieve symptoms, prevent complications, and improve the quality of life of people who have blood that leaks back into their heart’s left atrium. Mitral valve ...

Mitral valve prolapse treatments include medication to manage symptoms, lifestyle changes, and in people with severe cases, surgical intervention to repair or replace the mitral valve. Mitral valve ...